What is Ocrelizumab?
Category: Prescription Drugs
Most popular types: Ocrevus
Ocrelizumab is a type of monoclonal antibody that works by targeting certain types of cells in the immune system that are believed to contribute to the auto-immune destruction of nerve cells seen in multiple sclerosis.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Multiple sclerosis | 1605 | 156 | |
| Participate in clinical trial | 18 | 22 | |
| MS hug (tight chest or torso) | 4 | 8 | |
| Lhermitte's sign | 1 | 0 | |
| Losing train of thought | 1 | 0 | |
| Slow speech (bradyarthria) | 1 | 0 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 0 | |
| Moderate | 12 | |
| Mild | 41 | |
| None | 109 |
Duration
Stopped taking Ocrelizumab
| Duration | Patients | Percentage |
|---|---|---|
| Less than 1 month | 1 | |
| 1 - 6 months | 1 | |
| 6 months - 1 year | 3 | |
| 1 - 2 years | 7 | |
| 2 - 5 years | 2 | |
| 5 - 10 years | 2 |
What people switch to and from
Patients started taking Ocrelizumab after stopping:
| Treatment | Patients | Percentage |
|---|---|---|
| Natalizumab (Tysabri) | 50 | |
| Dimethyl fumarate (Tecfidera) | 37 | |
| Glatiramer acetate (Copaxone) | 35 | |
| Fingolimod (Gilenya) | 26 | |
| Teriflunomide (Aubagio) | 23 |
Patients stopped taking Ocrelizumab and switched to:
| Treatment | Patients | Percentage |
|---|---|---|
| Glatiramer acetate (Copaxone) | 2 | |
| Natalizumab (Tysabri) | 2 | |
| Rituximab (Rituxan) | 2 | |
| Cladribine (Mavenclad) | 1 | |
| Dimethyl fumarate (Tecfidera) | 1 |
Last updated: